Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?

Novo Nordisk (NYSE: NVO) started the GLP-1 weight-loss revolution that is sweeping the world. Its Wegovy/Ozempic shot was so popular that the company couldn't keep up with demand. That proved to be a major problem for the company, particularly after competitor Eli Lilly (NYSE: LLY) introduced its own GLP-1 weight-loss drug, Zepbound/Mounjaro, which enabled greater weight loss. But Novo Nordisk has been fighting back. Right now, that's all about its Wegovy pill. But a new partnership with Vivani Medical (NASDAQ: VANI) could flip the script on the entire GLP-1 industry. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool